A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia
CONCLUSION: Imatinib with low-dose ara-c can be considered as a potential first-line treatment option for CML-CP.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Priyanka Samal Prantar Chakrabarti Uttam K Nath Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | India Health | Leukemia | Oral Cancer | Study | Thrombocytopenia